Rimexolone

Drug Profile

Rimexolone

Alternative Names: AL-2178; FID 109980; ORG 6216; Rimexel; Trimexolone; Vexol; Vexolon

Latest Information Update: 15 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer Alcon; Schering-Plough
  • Class Anti-inflammatories; Antirheumatics; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Immunomodulators; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Ocular inflammation; Uveitis
  • No development reported Rheumatic disorders
  • Discontinued Dry eyes

Most Recent Events

  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top